Key result
Initiation and continuous adherence to an ARB versus an ACEI did not reduce the 4-year risk of amnestic mild cognitive impairment or probable dementia.
Why the study?
It was unclear whether the differing mechanistic effects between ARBs and ACEIs on the renin-angiotensin system translate to differential effects on clinical cognitive outcomes.
Does initiation and continuous adherence to an ARB versus ACEI reduce the risk of adjudicated mild cognitive impairment or dementia in older adults at high risk for cardiovascular disease?
Cohort (n=9,361)
Does initiation and continuous adherence to an ARB versus ACEI reduce the risk of adjudicated mild cognitive impairment or dementia in older adults at high risk for cardiovascular disease?
In older adults at high risk for cardiovascular disease, there is insufficient evidence to suggest a difference in the risk of mild cognitive impairment or dementia between initiating and adhering to an ARB compared to an ACEI.
Answers are grounded in this paper and cite their sources.
No difference in MCI/dementia risk with ARB versus ACEI; leaves open class-specific effects on cognition in high-CVD-risk older adults.
BACKGROUND: Whether the differing mechanistic effects between angiotensin-2 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) on the renin-angiotensin system translate to differential effects on clinical cognitive outcomes is unclear. METHODS: We employed an active comparator, new-user cohort study to emulate a target trial evaluating the per-protocol effect of initiating and continuously adhering to an ARB versus ACEI on adjudicated amnestic mild cognitive impairment (MCI) and probable dementia (PD) in the Systolic Blood Pressure Intervention Trial (SPRINT). Inverse probability of treatment and censoring weighted cumulative incidence functions accounted for confounding, the competing risk of death, adherence, and loss to follow-up. RESULTS: Of 9,361 SPRINT participants (mean age 67.1 ± 9.5 years, 36.7% female, 58.7% non-Hispanic White), 710 and 1,289 were new users of an ARB or ACEI. Overall, 291 (41.0%) ARB initiators and 854 (66.3%) ACEI initiators were nonadherent during follow-up. The IP-weighted 4-year probabilities of full adherence and being alive among ARB was 56.0% (95% CI: 52.2%-59.9%) and 30.5% (95% CI: 28.0%-33.1%) for ACEI. The 4-year weighted risk ratios (RR) for amnestic MCI/PD and for amnestic MCI/PD/death with initiation and full adherence to ARB versus ACEI were 0.94 (95% CI: 0.66-1.29) and 0.79 (95% CI: 0.58-1.06). The weighted 4-year weighted RR for all-cause death with ARB versus ACEI initiation and adherence was 0.36 (95% CI: 0.14-0.76). CONCLUSIONS: In this target trial emulation of older adults at high risk for cardiovascular disease, there was insufficient evidence to conclude a beneficial effect of initiating and continuously adhering to an ARB versus ACEI on adjudicated clinical cognitive outcomes.
No takes yet. Share an insight, caveat, or question.
Derington et al. (2025) conducted a cohort in High risk for cardiovascular disease (n=9,361). Angiotensin-2 receptor blockers (ARBs) vs. Angiotensin-converting enzyme inhibitors (ACEIs) was evaluated on Adjudicated amnestic mild cognitive impairment (MCI) and probable dementia (PD) (RR 0.94, 95% CI 0.66-1.29). Initiation and continuous adherence to an ARB versus an ACEI did not reduce the 4-year risk of amnestic mild cognitive impairment or probable dementia.
Synapse has enriched 10 related papers. Consider them for comparative context: